Bioatla.com

Bioatla.com has Server used 208.113.197.73 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2007-02-24 (14 years, 205 days) and hosted in Brea United States, server ping response time 43 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Bioatla keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Bioatlas
2 Bioatlantis
3 Bioatla s1
4 Bioatla adc
5 Bioatla cab
6 Bioatla pdf
7 Bioatla s-1
8 Bioatla ipo
9 Bioatla llc

Hosting Provider

Website: Bioatla.com
Hostname: apache2-grog.mitchell.dreamhost.com
Country:
NetName:
Address: 417 Associated Rd., PMB ,
Region: CA
City: Brea
Postal Code: 92821
Latitude: 33.926898956299
Longitude: -117.86119842529
Area Code: 714
Email Abuse1. [email protected]
2. [email protected]

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Revo.com (1 hours ago)

   » Bobbyjonesband.com (23 hours ago)

   » 1stchoiceautosllc.com (21 hours ago)

   » Huishoubao.com (2 day ago)

   » M1file.com (2 day ago)

   » Renhomesantalya.com (4 day ago)

   » Napadrivertours.com (3 day ago)

Results For Websites Listing

Found 45 Websites with content related to this domain, It is result after search with search engine

BioAtla Safer And More Effective Drugs For Cancer

Bioatla.com   DA: 15 PA: 15 MOZ Rank: 30

  • BioAtla ® is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer
  • Its Conditionally Active Biologics ™ (CAB) platform exploits the unique microenvironment of diseased tissue to more effectively target cancer.

BioAtla, Inc. (BCAB) Stock Price, News, Quote & History

Finance.yahoo.com   DA: 17 PA: 12 MOZ Rank: 30

  • (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor

BioAtla INC

Biocom.org   DA: 14 PA: 20 MOZ Rank: 36

  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California , and Beijing, China
  • BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.

BioAtla Stock Forecast, Price & News (NASDAQ:BCAB)

Marketbeat.com   DA: 18 PA: 20 MOZ Rank: 41

  • BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers
  • Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.

What Is BioAtla’s IPO Date And Price

Marketrealist.com   DA: 17 PA: 26 MOZ Rank: 47

  • BioAtla is a clinical-stage pharma company that's developing highly specific and selective antibody-based therapeutics for treating solid tumor cancers
  • The company has started Phase 2 trials for

BioAtla, Inc. (Form: S-1/A, Received: 12/08/2020 08:17:21)

Content.edgar-online.com   DA: 24 PA: 45 MOZ Rank: 74

  • Our business was founded in March 2007 and originally operated as a Delaware limited liability company, BioAtla, LLC
  • In July 2020, we converted from a limited liability company into a Delaware corporation pursuant to a statutory conversion and changed our name from BioAtla, LLC to BioAtla, Inc
  • pursuant to the LLC Conversion described above.

Have Insiders Sold BioAtla, Inc. (NASDAQ:BCAB) Shares

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 70

  • (NASDAQ:BCAB) shareholders may be a little concerned to see that the Co-Founder, Carolyn Short, recently sold a substantial US$5.0m worth of stock at a price of US$39.86 per share.

James Edmund Butler # 220201

Members.calbar.ca.gov   DA: 21 PA: 25 MOZ Rank: 53

BioAtla Announces Second Quarter 2021 Financial Results

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 75

BioAtla's investigational CAB CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer …

We're Not Very Worried About BioAtla's (NASDAQ:BCAB) Cash

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 73

  • BioAtla has a market capitalisation of US$1.4b and burnt through US$59m last year, which is 4.2% of the company's market value

BioAtla, Inc.

Facebook.com   DA: 16 PA: 29 MOZ Rank: 55

  • 70 likes · 14 talking about this · 1 was here
  • BioAtla is a leading integrated biological service company specializing in next generation protein and antibody

BCAB Stock Price BioAtla Inc. Stock Quote (U.S.: Nasdaq

Marketwatch.com   DA: 19 PA: 21 MOZ Rank: 51

  • engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer
  • Its CAB portfolio include MABs & ADCS, BA3011

Jobs With BioAtla

Biospace.com   DA: 16 PA: 25 MOZ Rank: 53

  • (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial public offering of 12,075,000 shares of common stock at a public offering price of $18.00 pe.

BioAtla Raises $72.5 Million In Series D Financing

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 81

  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and Beijing, China

BioAtla Company Profile

Craft.co   DA: 8 PA: 8 MOZ Rank: 30

  • BioAtla is a biopharmaceutical company that develops drugs for cancer
  • Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.

BioAtla Announces Second Quarter 2021 Financial Results

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 92

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro, a provider of

BioAtla LLC

Bloomberg.com   DA: 17 PA: 28 MOZ Rank: 61

  • BioAtla LLC is a biological service company
  • The Company specializes in next generation protein and antibody engineering for the pharmaceutical industry.

BioAtla Announces Second Quarter 2021 Financial Results

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 79

  • BioAtla's investigational CAB CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody
  • To learn more about BioAtla, Inc

Cancer Therapy BA3071 To Be Developed By BioAtla And BeiGene

Immuno-oncologynews.com   DA: 23 PA: 50 MOZ Rank: 91

  • BioAtla and BeiGene entered into a collaboration agreement for the development, production, and commercialization of BioAtla’s BA3071, an investigational anti-CTLA-4 checkpoint blockade antibody.
  • Checkpoint blockade therapies are based on the principle of removing the “brakes” of the immune system, in order to use the power of the body’s immune system to fight cancer faster and …

Ka-Ching! BioAtla Raises $72.5 Million Series D Round

Biospace.com   DA: 16 PA: 50 MOZ Rank: 85

  • San Diego-based BioAtla closed on a Series D financing round worth $72.5 million
  • The round was led by Soleus Capital and joined by new investors including HBM Healthcare Investments as co-lead, Cormorant Asset Management, Farallon Capital, Pappas Capital, funds managed by Janus Henderson, Boxer Capital, and one institutional investor.

BioAtla Insider Buying And Selling (NASDAQ:BCAB) MarketBeat

Marketbeat.com   DA: 18 PA: 35 MOZ Rank: 73

  • BioAtla (NASDAQ:BCAB) Insider Buying and Selling Activity
  • 35.50% of BioAtla's shares are owned by company executives, directors and other insiders
  • Over the past twelve months, insiders at the have sold shares 8 time (s), totalling $26,416,542.34
  • During the same time, BioAtla insiders have purchased shares 2 time (s), totalling $39,400,020.00.

BioAtla Raises $72.5 Million In Series D Financing News

Wfmz.com   DA: 12 PA: 50 MOZ Rank: 83

  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and Beijing, China
  • BioAtla develops novel monoclonal antibody and other protein therapeutic

BioAtla Company Profile: Stock Performance & Earnings

Pitchbook.com   DA: 13 PA: 26 MOZ Rank: 61

  • BioAtla General Information Description
  • BioAtla Inc is a clinical-stage biopharmaceutical company
  • The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

BioAtla (NasdaqGM:BCAB)

Simplywall.st   DA: 13 PA: 50 MOZ Rank: 86

  • BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers
  • Its lead product candidate is BA3011, a conditionally active bi

IPO: BioAtla

Renaissancecapital.com   DA: 26 PA: 25 MOZ Rank: 75

  • Phase 2 biotech developing selective antibody therapies for solid tumors
  • Latest Trade: $40.04 0.00 (0.0%) First Day Return: +72.3%
  • We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment

BioAtla, Inc. LinkedIn

Linkedin.com   DA: 16 PA: 16 MOZ Rank: 57

  • BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer

BCAB BioAtla Inc. Stock Overview (U.S.: Nasdaq) Barron's

Barrons.com   DA: 15 PA: 24 MOZ Rank: 65

  • engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

IPO Preview: BioAtla Begins $100 Million IPO Effort

Thestreet.com   DA: 17 PA: 21 MOZ Rank: 65

San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the …

BioAtla : Announces Second Quarter 2021 Financial Results

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 100

  • BioAtla's investigational CAB CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody
  • To learn more about BioAtla, Inc

BioAtla, Inc. (BCAB) Stock Price Today, Quote & News

Seekingalpha.com   DA: 16 PA: 12 MOZ Rank: 57

  • (BCAB) Stock Price Today, Quote & News | Seeking Alpha
  • Sep 2021Jul 2021May 2021Mar 2021Jan 2021Nov 2020

BioAtla, Inc. Hiring (Associate) Director, Clinical In San

Linkedin.com   DA: 16 PA: 50 MOZ Rank: 96

  • Apply for (Associate) Director, Clinical at BioAtla, Inc
  • Enter your email to apply with your existing LinkedIn profile, or to create a new one.

BioAtla Raises $72.5M Series D

Vcnewsdaily.com   DA: 15 PA: 43 MOZ Rank: 89

  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and Beijing, China
  • BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing

BCAB Stock Price Quote & News

Robinhood.com   DA: 13 PA: 12 MOZ Rank: 57

  • You can buy and sell BioAtla (BCAB) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news
  • Other Robinhood Financial fees may apply, check rbnhd.co/fees for details.

Bioatla Inc Stock Quote: BCAB Stock News, Quotes, Analysis

Research.investors.com   DA: 22 PA: 41 MOZ Rank: 96

  • Bioatla Earns IBD Rating Upgrade
  • Bioatla (BCAB) had its Relative Strength (RS) Rating upgraded from 68 to 72 Thursday -- a welcome improvement, but still Investor's Business Daily 05/13/2021 03:00 AM ET.

BioAtla VentureRadar

Ventureradar.com   DA: 20 PA: 50 MOZ Rank: 16

  • "BioAtla is a global biotechnology company with operations in San Diego, California, and Beijing, China
  • BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing.

Cell Line License Agreement With Life Technologies

Contracts.justia.com   DA: 20 PA: 45 MOZ Rank: 100

BioAtla, LLC (“LICENSEE”) is licensed to use certain Life Technologies Corporation products and technologies, including modifications to the [***] cell line and proprietary components, derivatives and progeny thereof produced by or on behalf of LICENSEE (collectively, “LICENSEE Modified Cells”) for clinical and commercial purposes.

CAB-AXL-ADC Safety And Efficacy Study In Adult And

Clinicaltrials.gov   DA: 18 PA: 21 MOZ Rank: 75

  • ClinicalTrials.gov Identifier: NCT03425279 Other Study ID Numbers: BA3011-001 : First Posted: February 7, 2018 Key Record Dates: Last Update Posted: June 16, 2020 Last Verified: June 2020 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided

IPO Alert: BioAtla (BCAB) Markets Insider

Markets.businessinsider.com   DA: 27 PA: 46 MOZ Rank: 13

  • IPO Alert: BioAtla (BCAB) RTTNews
  • (RTTNews) - San Diego, California-headquartered BioAtla, global clinical …

BioAtla Inc. (NASDAQ: BCAB) Stock: Looks Like An Option To

Stocksregister.com   DA: 18 PA: 50 MOZ Rank: 12

  • (NASDAQ:BCAB) price on Friday, August 27, rose 6.13% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $40.86
  • A look at the stock’s price movement, the close in the last trading session was $38.50, moving within a …

Scott Andrew Smith Net Worth, Biography & Insider Trading

Insidertrades.com   DA: 21 PA: 38 MOZ Rank: 98

  • BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers
  • Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.

Recently Analyzed Sites

Revo.com (1 hours ago)

Bobbyjonesband.com (23 hours ago)

1stchoiceautosllc.com (21 hours ago)

Huishoubao.com (2 day ago)

M1file.com (2 day ago)

Trekksoft.com (4 day ago)

Tibbo.com (21 hours ago)

Dienlanhquan3.com (7 seconds ago)

Tailspinbandsc.com (4 hours ago)

Dungscanada.com (3 hours ago)

Jfsorange.org (3 min ago)

Marloweslu.com (2 day ago)